In a non‑smoking 49‑year‑old Caucasian male taking vortioxetine (Brintellix) 20 mg daily, trazodone (Trittico) 150 mg nightly, testosterone enanthate and anastrozole (Arimidex) 0.25 mg every four days, who after testosterone cessation had low testosterone and whose hematocrit is now elevated despite prior phlebotomy, what are the appropriate next management steps?

Management of Testosterone-Induced Erythrocytosis

You must immediately reduce or temporarily discontinue testosterone therapy until hematocrit normalizes below 54%, then switch from intramuscular testosterone enanthate to a transdermal formulation (gel or patch) which carries significantly lower risk of erythrocytosis. 1

Immediate Actions Required

Discontinue Current Testosterone Regimen

• Stop testosterone enanthate injections immediately – your hematocrit of 54% exceeds the clinical threshold where therapy modification is mandated 1, 2
• Intramuscular testosterone enanthate causes erythrocytosis in 43.8% of patients (defined as hematocrit >52%), compared to only 15.4% with transdermal preparations 1
• The elevation above normal range poses grave cardiovascular consequences, particularly increased blood viscosity that could aggravate coronary, cerebrovascular, or peripheral vascular disease 1

Monitor Hematocrit Closely

• Recheck hematocrit every 2-4 weeks until it normalizes to <50% 1, 2
• Consider therapeutic phlebotomy if hematocrit remains elevated or if urgent normalization is needed 1

Long-Term Management Strategy

Switch to Transdermal Testosterone

Once hematocrit normalizes, restart testosterone using transdermal gel rather than injections 1, 3

• Transdermal testosterone gel increases mean hematocrit by only 3.0% (95% CI 1.8-4.3) compared to 4.0% (95% CI 2.9-5.1) with intramuscular testosterone enanthate/cypionate 3
• Transdermal patches show even lower risk with only 1.4% mean increase (95% CI 0.2-2.6) 3
• Network meta-analysis confirms intramuscular testosterone cypionate/enanthate produces significantly higher hematocrit increases compared to patches 3
• Intranasal testosterone gel (if available) shows no significant hematocrit change after 4 months of treatment, unlike intramuscular injections which increased hematocrit from 42.7% to 46.6% 4

Dosing Considerations

• Start with lower transdermal doses initially (e.g., testosterone gel 50 mg/day delivering 5 mg/day) which causes erythrocytosis in only 11.3% of patients 1
• Higher gel doses (100 mg/day delivering 10 mg/day) increase erythrocytosis risk to 17.9% 1
• Titrate dose based on testosterone levels and symptom response while monitoring hematocrit 1, 2

Addressing the Anastrozole (Arimidex) Issue

Discontinue Anastrozole

Stop the anastrozole 0.25 mg every 4 days – this medication is FDA-approved exclusively for postmenopausal women with breast cancer, not for men on testosterone therapy 5

• Anastrozole is indicated only for hormone receptor-positive breast cancer in postmenopausal women 5
• The erythrocytosis you experienced was associated with supraphysiologic levels of both bioavailable testosterone and estradiol in men receiving intramuscular injections 1
• Aromatase inhibitors in men on testosterone therapy lack evidence-based support and may contribute to adverse effects

Monitoring Protocol After Restart

Hematocrit Surveillance

• Check hematocrit at 3 months after initiating transdermal therapy (most changes occur in first 3 months) 1
• Continue monitoring every 3-6 months during the first year 1
• If hematocrit exceeds 54% again, decrease dose or withhold therapy until normalization 1, 2

Testosterone Level Monitoring

• Measure total and free testosterone 2-4 weeks after starting transdermal therapy to ensure adequate replacement 1
• Target physiologic testosterone levels (300-1000 ng/dL) to minimize erythrocytosis risk while maintaining symptom control 1

Critical Caveats

Cardiovascular Risk Assessment

• Your elevated hematocrit increases blood viscosity and thrombotic risk, though no testosterone-associated thromboembolic events have been definitively reported to date 1
• The 54% hematocrit threshold, while widely used, lacks robust scientific validation and may need individualization based on cardiovascular risk factors 6
• Ensure you have no underlying conditions that independently increase hematocrit (though genetic JAK mutations were excluded) 1

Why Injections Failed in Your Case

• Your dose escalation from 37.5 mg/week to 44 mg/week of testosterone enanthate, though relatively modest, still produced significant erythrocytosis 1
• Injectable testosterone creates supraphysiologic peak levels that stimulate erythropoiesis more than steady-state transdermal delivery 1, 3
• Even "low-dose" intramuscular protocols carry substantially higher erythrocytosis risk than transdermal alternatives 3, 4

Psychiatric Medication Considerations

• Continue vortioxetine (Brintellix) 20 mg and trazodone (Trittico) 150 mg as prescribed – these do not interact with testosterone therapy 7
• Vortioxetine 20 mg demonstrates superior efficacy for depression and anxiety symptoms and is well-tolerated 7